According to a research released by Future Market Insights, the Chronic Pulmonary Hypertension Treatment Market revenue will achieve a valuation of US$ 7 billion in 2023 and is predicted to reach a market value of US$ 11.4 billion by registering a CAGR of 5% from 2023 to 2033. The increasing prevalence of pulmonary hypertension and the increasing availability of effective treatment options are projected to generate considerable growth in the market in the coming years.
Pulmonary hypertension is a disorder that causes unusually high blood pressure in the pulmonary artery, which transports blood from the heart to the lungs. If left untreated, this might force the right side of the heart to work harder, leading to cardiac failure. Pulmonary hypertension can be caused by a number of reasons, including heredity, heart and lung illness, and drug or toxin exposure.
Request a Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16779
The increasing incidence of the disease is one of the primary drivers of the chronic pulmonary hypertension therapy industry. According to the Pulmonary Hypertension Association, pulmonary hypertension affects 10-15% of patients with chronic obstructive pulmonary disease (COPD) and 30-40% of individuals with idiopathic pulmonary fibrosis (IPF). Pulmonary hypertension is also more common in persons with connective tissue illnesses such as scleroderma and lupus.
The availability of effective treatment choices is another factor driving the growth of the Chronic Pulmonary Hypertension Treatment market. Several medications, including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, have been approved by regulatory authorities for the treatment of pulmonary hypertension. These drugs act by dilating the blood arteries in the lungs, lowering pulmonary artery pressure, and increasing blood flow.
Furthermore, rising pulmonary hypertension awareness among healthcare professionals and patients is expected to drive demand for effective treatment options. Pulmonary hypertension is frequently misdiagnosed or underdiagnosed, therefore raising awareness of the disease can help patients obtain timely and effective treatment.
Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16779
Key Takeaways from the Market Study
- From 2018 to 2022, the Chronic Pulmonary Hypertension Treatment market grew at a CAGR of 3.5%.
- The global Chronic Pulmonary Hypertension Treatment market is expected to grow with a 5% CAGR during 2023 to 2033.
- As of 2033, the Chronic Pulmonary Hypertension Treatment Market is expected to reach US$ 11.4 Billion.
- According to the FMI analysis, the oral route of administration accounts for the largest market share.
- North America is expected to possess 40% market share for the Chronic Pulmonary Hypertension Treatment market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Chronic Pulmonary Hypertension Treatment,” says an FMI analyst
Market Competition
Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial – Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.
- In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH). The article, titled “Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension,” is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.
Request Report Customization@
https://www.futuremarketinsights.com/customization-available/rep-gb-16779
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Chronic Pulmonary Hypertension Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of drug type, distribution channel, route of administration & region.
Key Segments Profiled in the Chronic Pulmonary Hypertension Treatment Industry Survey
By Drug Type:
- Endothelin Receptor Antagonists
- PDE-5 Inhibitors
- Prostacyclin Analogs
- SGC Stimulators
By Route of Administration:
- Oral
- Intravenous/Subcutaneous
- Inhalational
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
